Screener
Recursion Pharmaceuticals, Inc. RXRX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Recursion Pharmaceuticals, Inc.’s reported figures.
Based on the most recent quarter.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
FAQ
- What is Recursion Pharmaceuticals, Inc.'s debt-to-equity?
- Recursion Pharmaceuticals, Inc. (RXRX) reported debt-to-equity of 0.1× in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s debt-to-equity changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s debt-to-equity decreased by 26.9% year-over-year, from 0.1× to 0.1×.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s debt-to-equity?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s debt-to-equity has grown at a -1.1% compound annual growth rate (CAGR), from 0.1× to 0.1×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Recursion Pharmaceuticals, Inc.'s debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude